65岁以上退伍军人真实世界研究294499人：mNEXSPIKE相对有效率35.9%，《美国医学会杂志网络开放》11月11日刊出
马萨诸塞州剑桥报道 — Moderna 公司11月11日宣布，一项大型真实世界研究结果已刊于《美国医学会杂志网络开放》（JAMA Network Open），比较其新冠疫苗 mNEXSPIKE 与 Comirnaty 在65岁及以上美国退伍军人中的效果。分析纳入美国退伍军人健康管理局（VHA）294499名匹配参与者，覆盖2025至2026年呼吸道病毒季。本稿只报道研究事实，不作个体诊疗建议。
研究的主要结局为需就医的新冠感染，包括住院、急诊、紧急护理、门诊就诊与抗病毒治疗。与 Comirnaty 相比，mNEXSPIKE 对需就医新冠感染的相对疫苗有效率为35.9%（95%置信区间为20.4%至49.7%）；对新冠相关住院的相对疫苗有效率为47.0%（95%置信区间为5.4%至74.8%）；各单项结局的点估计均一致偏向 mNEXSPIKE。探索性分析中，对重大不良心血管事件住院的相对疫苗有效率为39.3%（95%置信区间为11.8%至57.0%）。
该回顾性、主动对照匹配队列研究纳入2025年8月27日至2026年1月31日期间接种 LP.8.1 配方 mNEXSPIKE 或 Comirnaty 的65岁及以上退伍军人，随访最长150天、至2026年5月1日，参与者按居住县与接种日历周匹配。公司与研究方同时说明，作为观察性真实世界分析，该研究存在残余混杂，包括检测行为差异、未记录的既往感染与疫苗可得性；以年长男性为主的退伍军人人群可能限制结果对更广人群的适用性，研究结果为关联性发现，不确立因果关系。公司称，该研究由 Moderna 资助，Moderna 参与研究设计、数据解读与文稿工作，但未实施研究、未收集、管理和分析数据。
Real-World Study of 294,499 Veterans Aged 65 and Older: mNEXSPIKE Shows 35.9 Percent Relative Effectiveness, Published in JAMA Network Open on November 11
CAMBRIDGE, Massachusetts — Moderna, Inc. announced on November 11 the publication in JAMA Network Open of a large real-world study evaluating the comparative effectiveness of its COVID-19 vaccine mNEXSPIKE and Comirnaty among U.S. Veterans aged 65 years and older during the 2025-2026 respiratory virus season. The analysis included 294,499 matched participants in the U.S. Veterans Health Administration (VHA). This item reports the study's facts only and offers no individual medical advice.
The study's primary outcome was medically attended COVID-19, including hospitalization, emergency room visits, urgent care, outpatient visits and antiviral treatment. mNEXSPIKE was associated with 35.9 percent relative vaccine effectiveness against medically attended COVID-19 compared with Comirnaty (95 percent CI: 20.4 to 49.7 percent), and with 47.0 percent relative vaccine effectiveness against COVID-19-associated hospitalization (95 percent CI: 5.4 to 74.8 percent), with point estimates consistently favoring mNEXSPIKE across all individual components. An exploratory analysis found 39.3 percent relative vaccine effectiveness for hospitalization involving a major adverse cardiovascular event (95 percent CI: 11.8 to 57.0 percent).
The retrospective, active-comparator matched cohort study included VHA-enrolled veterans aged 65 years and older who received an LP.8.1-formulated mNEXSPIKE or Comirnaty vaccine between August 27, 2025 and January 31, 2026, followed for up to 150 days or through May 1, 2026, matched by home county and calendar week of vaccination. The company and investigators note that, as an observational real-world analysis, the study is subject to residual confounding, including differences in testing behavior, undocumented prior infection and vaccine availability; that the predominantly older, male VHA population may limit generalizability; and that the findings are associative and do not establish causality. The study was supported by Moderna, which contributed to study design, data interpretation and manuscript work, while Moderna did not conduct the study or collect, manage or analyze the data.
来源：Moderna
发布：GSM·美国（发布链接）
图片来源：图：退伍军人医院（资料图）。经Wikimedia Commons。 / Photo: a veterans hospital (file photo). Via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story